MORE COMMON
THAN YOU THINK

Until recently, eosinophilic gastritis and/or eosinophilic duodenitis (EG/EoD) was thought to be a rare condition but prevalence had never been assessed in a prospective, systematic manner. Now, A LARGE PROSPECTIVE STUDY DESIGNED TO ASSESS THE PREVALENCE OF EG/EoD IN ADULTS with active, chronic gastrointestinal (GI) symptoms has been completed.1,2

PREVALENCE STUDY OVERVIEW

A multicenter, prospective study conducted across 20 sites in the United States (US)1

  • Adult patients (aged ≥18 and ≤80 years) had GI symptoms for ≥6 months without an organic cause1
  • Symptoms assessed: abdominal pain, abdominal cramping, bloating, diarrhea, early satiety, loss of appetite, nausea, and vomiting1

GI symptoms were recorded daily using a validated patient-reported outcome (PRO) questionnaire1,3

  • PRO questionnaire developed in accordance with US Food and Drug Administration guidance1,3
  • Patients who reported a daily average symptom severity score of ≥3/10 on any single symptom met the criteria for moderate-to-severe symptoms and were eligible for EGD1

Patients who met criteria for moderate-to-severe symptoms underwent esophagogastroduodenoscopy (EGD) with collection of 12 biopsies, including1

  • 8 gastric (4 body, 4 antral)
  • 4 duodenal (second and third part)
  • Pathologist was blinded to all patient demographic, clinical, and endoscopic data1

Systematic histopathologic evaluation focused on counting of eosinophils1,4

  • A minimum of 5 high-power fields (hpfs) were assessed per biopsy1

KEY PRIMARY ENDPOINT

  • EG/EoD histologic criteria were defined as peak counts of ≥30 eosinophils per hpf in at least 5 gastric hpfs and/or 3 duodenal hpfs1,3,4,6
  • Histologic criteria were agreed upon by experts5

PREVALENCE STUDY RESULTS

45% WERE FOUND TO HAVE EG/EoD1

In a study of 405 patients with moderate-to-severe GI symptoms who underwent EGD with biopsy

45% WERE FOUND TO HAVE EG/EoD1

  • Chronic, moderate-to-severe GI symptoms1
  • ≥30 eosinophils per high-power field (hpf) in gastric and/or duodenal biopsy1,a,b

Average duration of GI symptoms in patients who were found to have EG/EoD1

Percentage of patients with EG/EoD who were previously diagnosed with another GI condition1,c

PHYSICIAN PERSPECTIVE:
DR WILLIAM CHEY REVIEWS RECENT EG/EoD PREVALENCE STUDY RESULTS

Recent research indicates that EG/EoD may be a common cause of chronic, moderate-to-severe GI symptoms and may be misdiagnosed as a functional GI disorder1,7

These healthcare professionals serve as disease education speakers for Allakos to help share EG/EoD insights like those in these videos, in addition to performing other services for the company. They receive compensation for this work.

Hear from leading gastroenterologist William Chey, MD

EG/EoD IS OFTEN OVERLOOKED AND UNDERDIAGNOSED1

References: 1. Talley NJ, Kamboj AP, Chey WD, et al. Endoscopy and systematic biopsy of patients with chronic gastrointestinal symptoms leads to high discovery rate of patients who meet histologic criteria for eosinophilic gastritis and/or eosinophilic duodenitis. Presented at: Digestive Disease Week Virtual; May 22, 2021.  2. Gonsalves N, Chehade M, Rothenberg ME, et al. Eosinophilic gastritis and eosinophilic duodenitis exhibit a similar clinical presentation, underscoring the need for collection of multiple biopsies from both the stomach and duodenum to evaluate for tissue eosinophilia. Poster presented at: Digestive Disease Week Virtual; May 21, 2021.  3. Dellon ES, Peterson KA, Murray JA, et al. Monoclonal antibody for eosinophilic gastritis and duodenitis. N Engl J Med. 2020;383(17):1624-1634. doi:10.1056/NEJMoa2012047.  4. Dellon ES, Gonsalves N, Rothenberg ME, et al. Determination of biopsy yield that optimally detects eosinophilic gastritis and/or duodenitis in a randomized trial. Clin Gastroenterol Hepatol. 2021;S1542-3565(21)00592-9. doi: 10.1016/j.cgh.2021.05.053.  5. Dellon ES, Peterson KA, Murray JA, et al. Monoclonal antibody for eosinophilic gastritis and duodenitis [trial protocol]. N Engl J Med. 2020;383(17):1-266. doi:10.1056/NEJMoa2012047.  6. Gonsalves N. Eosinophilic gastrointestinal disorders. Clin Rev Allergy Immunol2019;57(2):272-285. doi:10.1007/s12016-019-08732-1.  7. Chehade M, Kamboj AP, Atkins D, et al. Diagnostic delay in patients with eosinophilic gastritis and/or duodenitis: a population-based study. J Allergy Clin Immunol Pract. 2021;9(5):2050-2059.e20. doi:10.1016/j.jaip.2020.12.054.